In short
Dacarbazine Citrate is a chemotherapy medication being studied in clinical trials for various types of cancer, particularly melanoma and Hodgkin lymphoma. This article explores the use of Dacarbazine Citrate in ongoing clinical trials, its potential benefits, and what patients should know about participating in these studies.
At a glance
- Drug Name
- Dacarbazine Citrate
- Drug Class
- Alkylating agent
- Administration
- Intravenous infusion
- Cancer Types Studied
- Advanced Hodgkin Lymphoma, Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma, Soft Tissue Sarcoma
- Trial Phases
- Phase II and Phase III
- Key Endpoints
- Progression-Free Survival, Overall Survival, Safety and Tolerability
- Dosage Range
- Varies by trial; up to 1000 mg/m² reported
- Treatment Duration
- Varies by trial; up to 21 days per cycle reported
- Combination Therapies
- Often studied in combination with other drugs (e.g., Brentuximab Vedotin, Trametinib)
What is Dacarbazine?
Dacarbazine, also known as DACARBAZINE CITRATE, is a chemotherapy medication used to treat various types of cancer. It belongs to a class of drugs called alkylating agents, which work by damaging the DNA of cancer cells, preventing them from dividing and growing.
Medical Uses
Dacarbazine is primarily used in the treatment of:
- Advanced Hodgkin Lymphoma: It is often used as part of combination chemotherapy regimens for patients with advanced-stage Hodgkin lymphoma.
- Metastatic Melanoma: Dacarbazine is used in the treatment of unresectable or metastatic melanoma, particularly in cases where the cancer has a specific genetic mutation called NRAS.
- Soft Tissue Sarcoma: It may be used as part of a combination therapy for certain types of soft tissue sarcomas.
How It Works
Dacarbazine is a prodrug, which means it needs to be activated in the body to become effective. Once activated, it works by:
- Damaging the DNA of cancer cells
- Interfering with cell division
- Causing cancer cells to die
This mechanism of action helps to slow or stop the growth of cancer cells in the body.
Administration
Dacarbazine is typically administered in the following ways:
- Intravenous (IV) infusion: The drug is given directly into a vein over a period of time.
- Injection: In some cases, it may be given as an injection.
The method of administration will be determined by your healthcare provider based on your specific condition and treatment plan.
Dosage
The dosage of Dacarbazine can vary depending on the specific condition being treated, the patient's body surface area, and other factors. Some general dosage information includes:
- For advanced Hodgkin lymphoma, doses may range up to 375 mg/m² (milligrams per square meter of body surface area) per day.
- For metastatic melanoma, doses may be up to 1000 mg/m² per day.
- For soft tissue sarcoma, doses of up to 900 mg/m² per day have been used in clinical trials.
It's important to note that these are general ranges, and your actual dosage will be determined by your healthcare provider.
Side Effects
Like all chemotherapy drugs, Dacarbazine can cause side effects. Common side effects may include:
- Nausea and vomiting
- Loss of appetite
- Fatigue
- Lowered blood cell counts, which can increase risk of infection or bleeding
- Hair loss
- Skin reactions
More serious side effects can occur, and it's important to report any unusual symptoms to your healthcare provider immediately.
Precautions
Before receiving Dacarbazine, inform your healthcare provider if you:
- Have any allergies
- Have liver or kidney problems
- Are pregnant or planning to become pregnant
- Are breastfeeding
- Have any other medical conditions
Dacarbazine can interact with other medications, so be sure to inform your doctor about all medications, supplements, and herbal products you are taking.
Ongoing Research
Dacarbazine continues to be studied in clinical trials, often in combination with other treatments. For example:
- It is being investigated as part of a combination therapy for advanced Hodgkin lymphoma, alongside drugs like Brentuximab Vedotin.
- In metastatic melanoma, it is being compared to newer targeted therapies and immunotherapies to determine the most effective treatment approaches.
- For soft tissue sarcomas, researchers are studying its effectiveness as part of multi-drug chemotherapy regimens.
These ongoing studies aim to improve treatment outcomes and quality of life for patients with various types of cancer.